Castle Creek Biosciences

Krystal Biotech

This biotechnology company develops and commercialises redosable gene therapies for patients with rare genetic diseases, including dystrophic epidermolysis bullosa.

Mariposa Therapeutics

This biotechnology company develops a topical small-molecule therapy for patients with the rare genetic skin condition epidermolysis bullosa simplex.

Stridebio

This company develops engineered viral vectors and gene therapies for patients with rare genetic diseases.

Aurealis Pharma

This company develops cell and gene therapies for patients suffering from chronic wounds, cancer and inflammatory diseases.

Rocket Pharma

This company develops gene therapies for patients with rare and devastating genetic cardiovascular and haematological diseases.

Code Bio

This company develops non-viral genetic medicine delivery platforms and therapies for patients with rare and prevalent genetic diseases.

Aegle Therapeutics

This company develops extracellular vesicle therapies derived from stem cells to treat patients with rare dermatological disorders and severe burns.

Solid Biosciences

This life science company develops gene therapy candidates for patients living with rare neuromuscular and cardiac diseases.